These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31094024)

  • 21. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Underactive bladder in aging rats is associated with a reduced number of serotonin-expressing cells in the urethra and is improved by serotonin application to the urethra.
    Coelho A; Charrua A; Oliveira R; Cavaleiro H; Cruz CD; Cruz F
    Low Urin Tract Symptoms; 2019 Sep; 11(4):248-254. PubMed ID: 31250566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acotiamide hydrochloride hydrate added to combination treatment with an α-blocker and a cholinergic drug improved the QOL of women with acute urinary retention: case series.
    Sugimoto K; Akiyama T; Shimizu N; Matsumura N; Hashimoto M; Minami T; Nose K; Nozawa M; Yoshimura K; Uemura H
    Res Rep Urol; 2017; 9():141-143. PubMed ID: 28861403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs.
    Nagahama K; Matsunaga Y; Kawachi M; Ito K; Tanaka T; Hori Y; Oka H; Takei M
    Neurogastroenterol Motil; 2012 Jun; 24(6):566-74, e256. PubMed ID: 22429221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron.
    Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
    Arch Gerontol Geriatr; 2015; 61(2):212-6. PubMed ID: 26169181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
    Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
    Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term functional change of cryoinjury-induced detrusor underactivity and effects of extracorporeal shock wave therapy in a rat model.
    Chuang YC; Tyagi P; Luo HL; Lee WC; Wang HJ; Huang CC; Chancellor MB
    Int Urol Nephrol; 2019 Apr; 51(4):617-626. PubMed ID: 30796726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Verification of a false positive in a two-year rat carcinogenicity study using dual control groups.
    Ogawa S; Kuroda H; Kinomoto T; Kawabata Y; Kawabe M; Suguro M; Oishi Y
    J Toxicol Sci; 2018; 43(9):557-563. PubMed ID: 30185696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
    McNeill SA; Hargreave TB; Geffriaud-Ricouard C; Santoni J; Roehrborn CG
    Urology; 2001 Mar; 57(3):459-65. PubMed ID: 11248620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of Ubretid on bladder function after recent complete spinal cord injury.
    Smith PH; Cook JB; Prasad EW
    Br J Urol; 1974 Apr; 46(2):187-92. PubMed ID: 4823891
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical study of bunazosin hydrochloride, an alpha 1-adrenergic blocker, in benign prostatic obstruction and neurogenic bladder dysfunction].
    Takita T; Kondo A; Mitsuya H; Otani T
    Hinyokika Kiyo; 1987 Sep; 33(9):1375-84. PubMed ID: 2449057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of adding behavioural treatment or antimuscarinic drug therapy to α-blocker therapy in men with nocturia.
    Johnson TM; Markland AD; Goode PS; Vaughan CP; Colli JL; Ouslander JG; Redden DT; McGwin G; Burgio KL
    BJU Int; 2013 Jul; 112(1):100-8. PubMed ID: 23448285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of voiding function and structural bladder changes in a rat model of neurogenic underactive bladder disease.
    Weyne E; Dewulf K; Deruyer Y; Rietjens R; Everaerts W; Bivalacqua TJ; De Ridder D; Van der Aa F; Albersen M
    Neurourol Urodyn; 2018 Jun; 37(5):1594-1604. PubMed ID: 30105760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Male lower urinary tract symptoms: treatment with a-blockers, 5-a-reductase inhibitors, antimuscarinics, or a combination.
    Appell RA
    Curr Urol Rep; 2007 Sep; 8(5):370-2. PubMed ID: 17880835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of combination of Ea-0643 (bunazosin hydrochloride) and bethanechol chloride in patients with neurogenic bladder].
    Araki T; Nakano S; Sugimura Y; Tochigi H; Kawamura J; Kato T; Tajima K; Chigusa I; Saito K; Morisita H
    Hinyokika Kiyo; 1990 Nov; 36(11):1379-83. PubMed ID: 1981126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study.
    Takeda M; Yokoyama O; Yoshida M; Nishizawa O; Hirata K; Nakaoka R; Takita Y; Murakami M
    Int J Urol; 2017 Jul; 24(7):539-547. PubMed ID: 28556284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg.
    Oh-oka H
    Urol Int; 2009; 82(2):136-42. PubMed ID: 19321997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinson's disease and prostate enlargement: Both contribute to overactive bladder in the elderly.
    Sakakibara R; Lee FC; Suzuki H; Tateno F; Kishi M; Aiba Y
    Int J Urol; 2018 Nov; 25(11):982-983. PubMed ID: 30155980
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.